Novocure's General Counsel Resigns After 10 Years of Service
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Treating Fields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Final data from INNOVATE-3 trial anticipated in 2023 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of
NVCR earnings call for the period ending September 30, 2021.
Final data collection is expected in the first half of 2022 Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab
/PRNewswire/ -- The EndBrainCancer Initiative (EBCI) recently hosted the first of a virtual "Know Your Treatment Options" Patient Education Meeting and Event...